文献速递外周动脉疾病

老年严重肢体缺血治疗的成本效益分析

Cost-effectiveness of the treatments for critical limb ischemia in the elderly population.
PubMed 文献 · J Vasc Surg · 2019-03-25

这项前瞻性观察队列研究在荷兰两家外周医院纳入195例70岁及以上、不适合手术的严重肢体缺血(CLI)患者,比较血管腔内血运重建、外科血运重建与保守治疗的成本效益,随访2年。结果显示,血管腔内血运重建相对保守治疗的增量成本效果比(ICER)为€38,247.41/QALY,低于荷兰适用阈值€80,000/QALY;在70–79岁和≥80岁亚组中亦具成本效益。

要点

  • 对不适合手术的70岁以上CLI患者,血管腔内血运重建相对保守治疗具成本效益。
  • 70–79岁与≥80岁亚组的ICER分别为€29,898.36/QALY与€56,810.14/QALY,均低于荷兰阈值。
  • 成本与效果绝对差异较小,临床决策仍需结合个体情况。

核心结论

  • 对70岁以上不适合手术的CLI患者,血管腔内血运重建相对保守治疗具成本效益,在≥80岁人群亦然。
  • 成本与效果绝对差异较小,医生还应考虑可能改变干预结局的个体情况。
  • 成本效益只是临床决策需要考虑的方面之一。

研究设计与样本

  • 前瞻性观察队列研究,数据来自荷兰两家外周医院。
  • 纳入70岁及以上CLI门诊患者,排除恶性肿瘤、语言能力不足和认知障碍者。
  • 195例纳入、192例排除,经多学科血管会议分为血管腔内血运重建、外科血运重建或保守治疗三组。
  • 按年龄做亚组分析(70–79岁与≥80岁),随访2年。
  • 用€/QALY的ICER量化血管腔内与保守治疗的成本效益。

主要发现

  • 基线时外科血运重建患者健康状态较好,血管腔内血运重建与保守治疗患者健康状态相当。
  • 血管腔内血运重建相对保守治疗的ICER为€38,247.41/QALY(约$50,869/QALY)。
  • 70–79岁亚组ICER为€29,898.36/QALY(约$39,765/QALY)。
  • ≥80岁亚组ICER为€56,810.14/QALY(约$75,557/QALY)。

关键数值与推荐

  • 荷兰适用成本效益阈值为€80,000/QALY(约$106,400/QALY)。
  • 血管腔内血运重建相对保守治疗的ICER为€38,247.41/QALY,低于上述阈值。
  • 70–79岁与≥80岁亚组ICER分别为€29,898.36/QALY与€56,810.14/QALY,均低于阈值。

临床怎么用

  • 对70岁以上不适合手术的CLI患者,可将血管腔内血运重建作为相对保守治疗具成本效益的选项。
  • 对≥80岁患者,血管腔内血运重建相对保守治疗仍具成本效益,可纳入决策讨论。
  • 因成本与效果绝对差异较小,应结合个体情况综合判断,成本效益仅为决策维度之一。

局限性

  • 为前瞻性观察队列研究,非随机分组,治疗分配经多学科血管会议决定。
  • 仅纳入荷兰两家外周医院患者,外推需谨慎。
  • 排除恶性肿瘤、语言能力不足和认知障碍者,结果不适用于这些人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The treatment of critical limb ischemia (CLI), with the intention to prevent limb loss, is often an intensive and expensive therapy. The aim of this study was to examine the cost-effectiveness of endovascular and conservative treatment of elderly CLI patients unsuitable for surgery. METHODS: In this prospective observational cohort study, data were gathered in two Dutch peripheral hospitals. CLI patients aged 70 years or older were included in the outpatient clinic. Exclusion criteria were malignant disease, lack of language skills, and cognitive impairment; 195 patients were included and 192 patients were excluded. After a multidisciplinary vascular conference, patients were divided into three treatment groups (endovascular revascularization, surgical revascularization, or conservative therapy). Subanalyses based on age were made (70-79 years and ≥80 years). The follow-up period was 2 years. Cost-effectiveness of endovascular and conservative treatment was quantified using incremental cost-effectiveness ratios (ICERs) in euros per quality-adjusted life-years (QALYs). RESULTS: At baseline, patients allocated to surgical revascularization had better health states, but the health states of endovascular revascularization and conservative therapy patients were comparable. With an ICER of €38,247.41/QALY (∼$50,869/QALY), endovascular revascularization was cost-effective compared with conservative therapy. This is favorable compared with the Dutch applicable threshold of €80,000/QALY (∼$106,400/QALY). The subanalyses also established that endovascular revascularization is a cost-effective alternative for conservative treatment both in patients aged 70 to 79 years (ICER €29,898.36/QALY; ∼$39,765/QALY) and in octogenarians (ICER €56,810.14/QALY; ∼$75,557/QALY). CONCLUSIONS: Our study has shown that endovascular revascularization is cost-effective compared with conservative treatment of CLI patients older than 70 years and also in octogenarians. Given the small absolute differences in costs and effects, physicians should also consider individual circumstances that can alter the outcome of the intervention. Cost-effectiveness remains one of the aspects to take into consideration in making a clinical decision.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Peters CML, de Vries J, Redeker S, et al. Cost-effectiveness of the treatments for critical limb ischemia in the elderly population. J Vasc Surg. 2019. PMID: 30922757. doi:10.1016/j.jvs.2018.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。